Exploring the How-To of

Commercializing New Modalities

Can leading organizations collaborate to ensure access to quality resources, engage with complementary organizations, and facilitate access to capital? We believe so!

A Unique Constellation of Life Science Organizations

New Modality Support (NMS) is a collaborative project supporting individual research within the national drug development initiatives OligoNova and CCRM Nordic. It focuses on therapeutic oligonucleotides and advanced therapies (ATMP). The constellation members combine their unique strengths to support early-stage life science companies in the Nordic region.

Sharing Knowledge to Provide Better Support

Success in therapeutic oligonucleotide and ATMP-specific drug development requires new knowledge and understanding. Incorporating research and commercialization strategies early increases a project’s chance of success.

Learn more

Sector
Expertise

We simplify the process of collaborating with specialists, including regulatory pathway expertise, as well as finding resources, programs and assistance available to help new and early-stage businesses.

Funding and Investments

Attractive and clear packaging of the investment case is important in order attract relevant investors. We help early-stage businesses navigate the investor landscape and build strong investor-company relationships.

Fostering Collaboration

NMS helps early-stage businesses in getting access to complementary organizations within the life science ecosystem such as incubators, arenas, hospitals and universities.